{
    "body": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21784350", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20189881", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23334069", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21263194", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22277519", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20360050", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20505438", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21504387", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19923550", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22473769", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21091109", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21592055", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23334070", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21987394", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16338209", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23574434", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20205639", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22134132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20154508", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23796662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21883222", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22292124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20375655", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19228370", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19585948"
    ], 
    "ideal_answer": [
        "Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", 
        "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"
    ], 
    "exact_answer": [
        [
            "Bapineuzumab", 
            "bapineuzumab"
        ], 
        [
            "Solanezumab", 
            "solanezumab"
        ], 
        [
            "Ponezumab", 
            "ponezumab"
        ], 
        [
            "Gantenerumab"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430", 
        "http://www.disease-ontology.org/api/metadata/DOID:10652", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000911", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016229", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016032", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986"
    ], 
    "type": "list", 
    "id": "52fc94db2059c6d71c000074", 
    "snippets": [
        {
            "offsetInBeginSection": 389, 
            "offsetInEndSection": 528, 
            "text": "The first active immunization clinical trial with AN1792 in AD patients was halted when a subset of patients developed meningoencephalitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205639", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 529, 
            "offsetInEndSection": 585, 
            "text": "The first passive immunotherapy trial with bapineuzumab,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205639", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 274, 
            "offsetInEndSection": 402, 
            "text": "Preliminary results of a prematurely terminated clinical trial where AD patients were actively vaccinated with aggregated Abeta ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16338209", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 112, 
            "offsetInEndSection": 203, 
            "text": "strategies based on A\u03b21-42 peptide induced encephalomyelitis and possible microhemorrhages.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23796662", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 649, 
            "offsetInEndSection": 852, 
            "text": "Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 853, 
            "offsetInEndSection": 957, 
            "text": "Solanezumab's two Phase III trials in AD patients failed to meet endpoints when analyzed independently. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 794, 
            "offsetInEndSection": 995, 
            "text": "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate A\u03b2 and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 997, 
            "offsetInEndSection": 1082, 
            "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 57, 
            "offsetInEndSection": 321, 
            "text": "several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22277519", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 267, 
            "offsetInEndSection": 608, 
            "text": "Several types of A\u03b2 peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact A\u03b2(42) , active immunization involving the administration of synthetic fragments of A\u03b2 peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against A\u03b2 peptide", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883222", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 447, 
            "offsetInEndSection": 641, 
            "text": "An active anti-A\u03b2 vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 853, 
            "offsetInEndSection": 1083, 
            "text": "The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-A\u03b2 monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce A\u03b2 burden in the brain of AD patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1331, 
            "offsetInEndSection": 1499, 
            "text": "The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-A\u03b2 immunization is able to alter the course if this devastating disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 125, 
            "offsetInEndSection": 353, 
            "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD. The drug is currently being investigated in Phase III trials as a disease-modifying treatment for AD. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 630, 
            "offsetInEndSection": 805, 
            "text": "The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-A\u03b2 monoclonal antibodies that has been tested in two Phase II trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091109", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1027, 
            "offsetInEndSection": 1218, 
            "text": "The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-A\u03b2 immunization is able to alter the course of this devastating disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091109", 
            "endSection": "abstract"
        }
    ]
}